Skip to main content

ADVERTISEMENT

Michael Attubato, MD

06/19/2008
The primary endpoint was the 30-day incidence of death, MI, urgent revascularization and major hemorrhage, which occurred in 9.2% of patients in the bivalirudin arm and 10.0% of patients in the heparin-IIb/IIIa arm. The trial had a...
The primary endpoint was the 30-day incidence of death, MI, urgent revascularization and major hemorrhage, which occurred in 9.2% of patients in the bivalirudin arm and 10.0% of patients in the heparin-IIb/IIIa arm. The trial had a...
The primary endpoint was the...
06/19/2008
Cath Lab Digest
Feature
06/19/2008
The primary endpoint was the 30-day incidence of death, MI, urgent revascularization and major hemorrhage, which occurred in 9.2% of patients in the bivalirudin arm and 10.0% of patients in the heparin-IIb/IIIa arm. The trial had a...
The primary endpoint was the 30-day incidence of death, MI, urgent revascularization and major hemorrhage, which occurred in 9.2% of patients in the bivalirudin arm and 10.0% of patients in the heparin-IIb/IIIa arm. The trial had a...
The primary endpoint was the...
06/19/2008
Cath Lab Digest
Original Contribution
01/03/2022
The initial wave of the coronavirus disease 2019 (COVID-19) pandemic resulted in an influx of patients with acute viral illness and profound changes in healthcare delivery in New York City. The impact of this pandemic on the presentation and...
The initial wave of the coronavirus disease 2019 (COVID-19) pandemic resulted in an influx of patients with acute viral illness and profound changes in healthcare delivery in New York City. The impact of this pandemic on the presentation and...
The initial wave of the...
01/03/2022
Journal of Invasive Cardiology